Cargando…
Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression
Fenofibrate slows the progression of clinical diabetic retinopathy (DR), but its mechanism of action in the retina remains unclear. Fenofibrate is a known agonist of peroxisome proliferator-activated receptor alpha (PPARα), a transcription factor critical for regulating metabolism, inflammation and...
Autores principales: | Enright, Jennifer M., Zhang, Sheng, Thebeau, Christina, Siebert, Emily, Jin, Alexander, Gadiraju, Veda, Zhang, Xiaodong, Chen, Shiming, Semenkovich, Clay F., Rajagopal, Rithwick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794763/ https://www.ncbi.nlm.nih.gov/pubmed/33396512 http://dx.doi.org/10.3390/jcm10010126 |
Ejemplares similares
-
Retinal de novo lipogenesis coordinates neurotrophic signaling to maintain vision
por: Rajagopal, Rithwick, et al.
Publicado: (2018) -
Altered Peroxisome Proliferator-Activated Receptor Alpha Signaling in Variably Diseased Peripheral Arterial Segments
por: Engel, Connor, et al.
Publicado: (2022) -
Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate
por: Osada, Miho, et al.
Publicado: (2014) -
Glucose-mediated de novo lipogenesis in photoreceptors drives early diabetic retinopathy
por: Rajagopal, Rithwick, et al.
Publicado: (2021) -
Quantification of retinal layer thickness changes in acute macular neuroretinopathy
por: Munk, Marion R, et al.
Publicado: (2017)